BioPharmSignal logoBioPharmSignal

Biotech News

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

Geron (GERN)GeronEarnings

Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

Related news

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

MMSIMerit Medical2026-10-06 20:30 EST

Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026

View all latest news

Geron

Telomerase-Targeted Hematology Company Geron is a commercial-stage biopharmaceutical company focused on blood cancers. Its scientific and commercial strategy is built around inhibiting telomerase, an enzyme involved in the continued proliferation of malignant cells. RYTELO in Lower-Risk MDS RYTELO, or imetelstat, is a first-in-class...

Recent company news

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

GERNGeron2026-10-19 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-09-18 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-09-02 12:00 EST

Geron to Present at Upcoming Investor Conferences

GERNGeron2026-08-18 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
1.16 USD
Market cap
750.58M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States